DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity - Wikidata - wikimedia - TriplyDB

DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity

DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity

http://www.wikidata.org/entity/Q30499197

about

Human ALKBH7 is required for alkylation and oxidation-induced programmed necrosis The implication and potential applications of high-mobility group box 1 protein in breast cancer NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphoma Inflammation and skeletal metastasis Comprehensive review of epidemiological and animal studies on the potential carcinogenic effects of nicotine per se Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation The proliferation rate paradox in antimitotic chemotherapy.Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation.Life after death: targeting high mobility group box 1 in emergent cancer therapies.Innate immune cells in breast cancer--from villains to heroes?Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.To Prime, or Not to Prime: That Is the Question.Neutrophils in cancer: neutral no more.Progress in tumor-associated macrophage (TAM)-targeted therapeutics.Ferroptosis: bug or feature?Autocrine DNA fragmentation of intra-epithelial lymphocytes (IELs) in mouse small intestine.Non-apoptotic routes to defeat cancer.Clinical and prognostic significance of high-mobility group box-1 in human gliomas.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.Granzyme B-dependent and perforin-independent DNA fragmentation in intestinal epithelial cells induced by anti-CD3 mAb-activated intra-epithelial lymphocytes.The Thyroid Hormone Inactivating Type 3 Deiodinase is Essential for Optimal Neutrophil Function - observations from 3 species.Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice.Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model.Macrophages: The Road Less Traveled, Changing Anticancer Therapy.Regulation of Intracellular Triiodothyronine Is Essential for Optimal Macrophage Function.Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo.

P2860

Q24339614-E83315EC-AF75-4BE4-97C6-1AD4D02C7A62 Q26744069-83E48C10-CB63-4919-BB9F-94D55289F8BA Q26746478-DBABBEF3-26BB-48B7-8D69-2E0191628F6D Q26780141-2D427EB3-61C0-4E4E-B48A-EE13E01F74A9 Q28396089-7E296F93-9022-4FCD-94DD-5143292C6174 Q28830476-CDA1A030-E291-40EB-B3A9-B28701C0FA35 Q34173568-4A89CC76-6022-45C8-8646-987E487D572C Q35059053-D8774499-CD03-457E-A46F-F5AA534C5558 Q35523700-0314084D-3715-4A48-8CB4-2572602D5B77 Q35591847-9A70E3AA-D8D3-4529-B169-A382124217ED Q35642841-B2515136-9C46-417C-9AF5-60AFEBAB8B6F Q35903509-B1676E69-2DC7-41EF-8FB8-380D2B213EA4 Q35924903-D5A884EA-CEAA-44E1-87B1-D168F616FEE3 Q36070093-E253E74E-128E-47B3-9A81-D92EE64D5448 Q36414193-86F5967D-437A-4271-B981-C83CD858093F Q36562901-534110D5-F9F1-44F7-9769-DC966026A254 Q37905673-2A45FF5C-C057-4E39-BFD8-3DB76BB91695 Q37991701-DCAAC936-A9DB-4D43-A9EE-7532BA2ADBEE Q38115968-EF0E490E-943D-4B30-8742-2E5D7267CE3B Q38798849-62663F48-5098-42E7-8D7C-3F15A5587AFF Q38860382-B1F72831-548B-4D75-AEA4-BB66B3A1DDC5 Q39267549-C2C70BBB-D46E-4E3A-831F-26A468911639 Q39277487-CADE7721-AA1D-4F16-89EC-EAA48CD73A4E Q41443672-596F9932-D246-4C45-980F-94A87198ADD6 Q41833885-95679E08-3361-4C03-A0E2-95E2CB5B134D Q41983273-6235FDE1-470D-4CBB-A7E6-4CB4F0AF09C3 Q42042886-B01307AA-AE87-417E-87E0-FBFBBFF5799D Q43673803-C72A8690-2928-4CA5-AB0C-B3BB46805D08 Q46251931-4FD7B422-8DC8-4941-A3BB-1B31A350F113 Q47149120-7B049F22-0AA3-4872-ADC1-060844C95065 Q48172033-9466AD82-9C0D-47CF-B6E8-5A4A792F84FC Q50109080-042F61C1-C161-48F6-8E0E-4015AF8E8A31 Q52321369-0A8D199C-70AB-488E-8DE8-464445D6F797 Q52592163-57266239-44B7-4F61-8D6D-14E413FC90E9 Q55259742-0011A92A-3F7C-41DC-BACE-0F7DF7E254E7

P2860

DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity

http://www.wikidata.org/entity/Q30499197

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

DNA alkylating therapy induces ...... activation of innate immunity

@ast

DNA alkylating therapy induces ...... activation of innate immunity

@en

type

label

DNA alkylating therapy induces ...... activation of innate immunity

@ast

DNA alkylating therapy induces ...... activation of innate immunity

@en

prefLabel

DNA alkylating therapy induces ...... activation of innate immunity

@ast

DNA alkylating therapy induces ...... activation of innate immunity

@en

P1433

Q30499197-4604D1F2-57D5-49BA-A1C9-85B8E23093F5

P1476

Q30499197-9E68F846-3825-4210-82F8-B4B701E52081

P2093

Q30499197-094CE482-E2EF-4320-8282-EEA02593E1D6

Q30499197-32DEF558-F5F6-4B73-AB35-E1512D1617D1

Q30499197-7439CE63-E377-4D61-B925-6D47A419DBBE

Q30499197-86B2DF5E-130C-44D6-BA77-CCC6F82F4DA2

Q30499197-8767C417-E8C1-424C-9D82-A163B2CBEDB5

Q30499197-C3E68349-D484-4797-B135-ECE622E32322

Q30499197-CC385BDA-E8F8-4EBB-A992-7B9899202886

Q30499197-EA70BB3E-13B8-4DB0-8010-3AAAA0DB01BB

P2860

Q30499197-00B933F4-09D2-4268-9F36-AB69E0C46DD9

Q30499197-0F6D881B-28D4-4428-AED3-CE7E0B739DC8

Q30499197-15B5FE6C-8376-4D81-9292-9717034F2FBB

Q30499197-1AA54B6B-F818-4157-BA7C-A59751FE1970

Q30499197-1E953922-66D7-42CE-8C60-A80C29E30572

Q30499197-20229826-62EC-4A6B-83E2-B80ABB2A634A

Q30499197-22E15AD0-0F44-40D4-9D09-F24CA5D2EB4C

Q30499197-2D1421D2-A3BE-4492-ADEC-2640CB1D92DE

Q30499197-2E8AAA88-6B08-48A8-8E7B-EBBA1E3AC542

Q30499197-2F11D68B-2C14-483D-BF73-938169483281

P304

Q30499197-E29E997D-7AC0-45DA-90EA-411811D93545

P31

Q30499197-7F2B9F8B-433F-4A02-A130-888996BE62F6

P356

Q30499197-112345C7-2A56-4336-BB17-C5C5A9C9A67B

P407

Q30499197-939C812F-C773-47A3-8382-629201768CE8

P433

Q30499197-731A92D6-B498-41DD-BECF-2F33BBC7F3AA

P478

Q30499197-A13ECF78-8EF1-4E01-95F0-4354072D7599

P577

Q30499197-33E7FFBF-5BBC-4AED-A4C2-86673C5EE28F

P5875

Q30499197-F087CC10-22BC-4D67-AF9F-8EE369022411

P698

Q30499197-6EDB7590-FBED-4483-BF3C-82B78610069F

P932

Q30499197-F1AA35A1-008D-4511-8EBF-031ABC210638

P356

JIMMUNOL.1003267

P1433

Journal of Immunology

P1476

DNA alkylating therapy induces ...... activation of innate immunity

@en

P2093

Dara Ditsworth

http://www.w3.org/2001/XMLSchema#string

Gregory Sabino

http://www.w3.org/2001/XMLSchema#string

Howard C Crawford

http://www.w3.org/2001/XMLSchema#string

Jennifer L Guerriero

http://www.w3.org/2001/XMLSchema#string

Joseph M Catanzaro

http://www.w3.org/2001/XMLSchema#string

Martha B Furie

http://www.w3.org/2001/XMLSchema#string

Richard R Kew

http://www.w3.org/2001/XMLSchema#string

Wei-Xing Zong

http://www.w3.org/2001/XMLSchema#string

P2860

Endogenous HMGB1 regulates autophagy

Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein

Inflammation and cancer

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

HMG-1 as a late mediator of endotoxin lethality in mice

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD

HMGB1 and RAGE in inflammation and cancer

Masquerader: high mobility group box-1 and cancer

P304

3517-3526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1003267

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

186

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49817023

http://www.w3.org/2001/XMLSchema#string

P698

21300822

http://www.w3.org/2001/XMLSchema#string

P932

3066027

http://www.w3.org/2001/XMLSchema#string